Scientists test Two-Pronged attack on spreading prostate cancer
NCT ID NCT03737370
Summary
This early-stage study tested the safety of combining two existing cancer treatments—a chemotherapy drug (docetaxel) and a bone-targeting radiation drug (radium-223)—for men with advanced prostate cancer that has spread to the bones and stopped responding to standard hormone therapy. The main goal was to find the safest dose of this combination and see what side effects occurred. The study also looked at whether the treatment could help control the cancer and improve patients' quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Lahey Hospital & Medical Center
Boston, Massachusetts, 01805, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Tufts Medical Center
Boston, Massachusetts, 02111, United States
Conditions
Explore the condition pages connected to this study.